	US 12,268,702 B2
	Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent
Pan Li, Pingdingshan (CN); Limin Jia, Pingdingshan (CN); Zhiyong Qin, Pingdingshan (CN); and Zhaoyang Wang, Pingdingshan (CN)
Assigned to HENAN GENUINE BIOTECH CO., LTD., Pingdingshan (CN)
Filed by HENAN GENUINE BIOTECH CO., LTD., Pingdingshan (CN)
Filed on May 22, 2023, as Appl. No. 18/200,000.
Claims priority of application No. 202310201602.2 (CN), filed on Mar. 3, 2023.
Prior Publication US 2024/0293438 A1, Sep. 5, 2024
Int. Cl. A61K 31/7068 (2006.01); A61K 31/337 (2006.01); A61K 31/655 (2006.01); A61K 31/675 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)

CPC A61K 31/7068 (2013.01) [A61K 31/337 (2013.01); A61K 31/655 (2013.01); A61K 31/675 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01)]

3 Claims

1. A method for treating a tumor-related disease, comprising administering a synergistic pharmaceutical composition, comprising

(i) azvudine or a pharmaceutically acceptable salt, a stereoisomer or an isotopic derivative thereof; and

(ii) cyclophosphamide,

to a subject in need thereof; wherein the tumor-related disease is selected from the group consisting of malignant lymphoma, and leukemia.